refractory diffuse large B-cell lymphoma enrolled in the LOTIS-2 clinical trial

Overview of attention for article published in Clinical Cancer Research, October 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 5 X users

Readers on

mendeley: 13 Mendeley

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 9,818 followers.

https://t.co/acb4rN0cMQ

PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial https://t.co/wnNrlQRIar

RT @JuanAlderuccio: New paper out in @CCR_AACR! We demonstrated robust risk-stratification of pretreatment metabolic tumor volume and other…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.